Pro-Dex (NASDAQ:PDEX) Releases Earnings Results, Beats Expectations By $0.11 EPS

Pro-Dex (NASDAQ:PDEX) issued its earnings results on Thursday. The medical instruments supplier reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.11, Yahoo Finance reports. Pro-Dex had a net margin of 4.13% and a return on equity of 6.50%. The firm had revenue of $15.03 million during the quarter.

Pro-Dex Stock Up 4.6 %

PDEX stock opened at $23.28 on Friday. The stock has a market cap of $79.62 million, a P/E ratio of 40.14 and a beta of 0.38. The company has a current ratio of 3.45, a quick ratio of 2.08 and a debt-to-equity ratio of 0.25. Pro-Dex has a twelve month low of $14.51 and a twelve month high of $24.74. The company’s 50 day moving average is $19.73 and its two-hundred day moving average is $18.85.

Insider Activity

In related news, Director Angelita Rebamontan Domingo sold 2,585 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $18.30, for a total value of $47,305.50. Following the completion of the sale, the director now directly owns 8,191 shares of the company’s stock, valued at $149,895.30. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 42.60% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.